Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

Core Insights - Caris Life Sciences will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call to discuss these results [1] Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, focused on developing and commercializing innovative healthcare solutions [2] - The company utilizes comprehensive molecular profiling, including Whole Genome, Whole Exome, and Whole Transcriptome Sequencing, combined with advanced AI and machine learning to analyze the molecular complexity of diseases [2] - Caris has established a large-scale, multimodal clinico-genomic database and computing capability, which supports the development of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development [2] Company Background - Founded with the vision to harness the potential of precision medicine to enhance human health, Caris Life Sciences is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [3] - The company or its distributor partners provide services in the U.S. and various international markets [3]